| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | Telomir-1 (Telomir-Zn) Breast cancer | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | |
Pre-clinical data readout example | Telomir-1 (Telomir-Zn) Breast cancer | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology | |
Pre-clinical data readout example | Telomir-1 (Telomir-Zn) Breast cancer | Pre-clinical | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Telomir Pharmaceuticals, Inc.$1.27
-0.03 (-2.31%)
D 24Pipeline Score Richly Valued Pharma · Clinical
Market Cap
88.72 M
EPS
-0.29
P/E Ratio
-
Value Trade
91.78 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
467.80 K
Operating CF
-1.77 M
Total Assets
5.79 M
Total Liabilities
827.31 K
Equity
4.96 M
D/E Ratio
12,345
1.57 %
Week
-7.86 %
1 Month
14.16 %
3 Month
-9.79 %
6 Month
-81.57 %
5 Year
-81.57 %
All Time
Cash Data
Cash Position
5.56 M
Monthly Burn
591.00 K
Runway
7.7 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
47.05 K
52 Week Range
1.05 - 3.10
% held by Insiders
73.12 %
% held by Institutions
3.26 %
Enterprise Value
83.36 M
Total Shares
34.41 M
Short %
5.1 %
Float Shares
11.25 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Telomir Pharmaceuticals, Inc.
42Total events
3Upcoming
1Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 3
Event history 39
Jun 22, 2026
◆Oral PresentationTelomir-ZnPresentation
Presentation at BIO International Convention
cancer and agingsource ↗
Jun 15, 2026
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity with Telomir-Zn in a diet-induced zebrafish model of T2DM
Type 2 diabetes mellitussource ↗
Jun 15, 2026
▲IND ClearanceTelomir-ZnIND
FDA IND clearance for Phase 1/2 clinical trial in advanced or metastatic triple-negative breast cancer
Triple-negative breast cancersource ↗
May 20, 2026
▲PublicationTelomir-ZnPresentation
Peer-reviewed publication of Telomir-Zn preclinical data in Wilson's disease model in Advances in Redox Research
Wilson's diseasesource ↗
Apr 17, 2026
Apr 2026
▲IND ClearanceTelomir-1IND
FDA IND clearance for Phase 1/2 trial in Triple-Negative Breast Cancer
Triple-Negative Breast Cancersource ↗
Mar 23, 2026
◆Oral PresentationTelomir-ZnPresentation
Presentation at 16th World Congress on Breast Cancer Research & Therapies
breast cancersource ↗
Feb 17, 2026
▲Preclinical PoCTelomir-1Preclinical
Telomir-1 demonstrates iron-dependent tumor cell mortality in human TNBC cell lines
triple-negative breast cancersource ↗
Feb 5, 2026
▲Preclinical PoCTelomir-ZnPreclinical
New cellular data showing Telomir-Zn modulates intracellular zinc and iron
cancer and agingsource ↗
Jan 5, 2026
▲Preclinical PoCTelomir-1Preclinical
Telomir-1 demonstrated statistically significant reductions in primary tumor growth and metastatic dissemination in TNBC animal models
triple-negative breast cancersource ↗
Q1 2026
●IND SubmissionTelomir-1IND
IND submission for Telomir-1 planned in Q1 2026
triple-negative breast cancersource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 22%
Micro Cap (rank 707 of 905)
Percentile RankTelomir Pharmaceuticals, Inc. faces pipeline headwinds (24/100), with $28M risk-adjusted pipeline value, led by Zn-Telomir in Triple-Negative Breast Cancer (TNBC) (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zn-Telomir Small molecule | Triple-Negative Breast Cancer (TNBC) | Phase 1 | NCT07581314 | 5% | $28M | NOT YET_RECRUITING | 76 | - | D (33) | Nov 1, 2027 | - | MEDIUM Jun 23, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Telomir-1 | triple-negative breast cancer | — | 2026-01-05 | statistically significant reductions in primary tumor growth; statistically significant activity on both tumor growth and cancer cell spread; greater tumor growth inhibition than either agent alone Read More | Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Read More | |
Telomir-1 | triple-negative breast cancer | — | 2026-01-05 | statistically significant reductions in primary tumor growth; statistically significant activity on both tumor growth and cancer cell spread; greater tumor growth inhibition than either agent alone Read More | Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Read More | |
Telomir-1 | triple-negative breast cancer | — | 2026-01-05 | statistically significant reductions in primary tumor growth; statistically significant activity on both tumor growth and cancer cell spread; greater tumor growth inhibition than either agent alone Read More | Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TELO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TELO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TELOTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model Insulin Resistance Was
Telomir Pharmaceuticals has announced the publication of preclinical data in the journal 'Biomedicine & Pharmacotherapy,' demonstrating that Telomir-Zn restores insulin sensitivity in a zebrafish model of Type 2 diabetes. The study showed significant improvements in glucose metabolism and insulin resistance following 14 days of treatment. This reinforces the evidence supporting Telomir-Zn's mechanism of action geared towards correcting intracellular metal homeostasis, which is implicated in metabolic diseases. The findings contribute to Telomir's development of Telomir-Zn as a therapeutic candidate for conditions such as Type 2 diabetes and triple-negative breast cancer.
Read more →TELOTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease Study Published in Advances in Redox Research Demonstrated D
Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of data regarding Telomir-Zn, showcasing its effectiveness in improving survival rates and multiple endpoints in a preclinical model of Wilson's disease. The published study highlighted significant benefits, including reduced hepatic copper burden, enhanced liver biomarkers, and improved locomotor function. Importantly, the findings underscore the therapeutic potential of Telomir-Zn in addressing the oxidative stress and mitochondrial dysfunction associated with Wilson's disease. This marks a significant scientific milestone for Telomir, aligning with the ongoing development of their lead program for Triple-Negative Breast Cancer.
Read more →TELOTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals announced promising in vitro data showing that its compound, Telomir-Zn, induces significant tumor cell mortality across various subtypes of triple-negative breast cancer (TNBC). The mechanism is linked to iron modulation, with studies confirming that tumor cell death is iron-dependent. The company is preparing for an Investigational New Drug submission in early 2026, following successful preclinical results.
Read more →TELOTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Telomir Pharmaceuticals has reported new findings on Telomir-Zn, demonstrating its ability to modulate intracellular metal balance, which is linked to oxidative stress and genomic integrity. The study shows that Telomir-Zn increases zinc levels while reducing redox-active iron, suggesting a novel mechanism for addressing cancer and aging. The company plans to present these findings at several upcoming scientific meetings.
Read more →TELOTelomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Telomir Pharmaceuticals announced that Telomir-1 showed significant efficacy in reducing tumor growth and metastasis in aggressive triple-negative breast cancer (TNBC) animal models. The study highlighted that Telomir-1, both alone and in combination with paclitaxel, effectively inhibited tumor growth in models with varying chemotherapy responsiveness. These findings underscore the potential for personalized treatment strategies in TNBC.
Read more →TELOTelomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
Telomir Pharmaceuticals announced the passing of its Chairman and CEO, Dr. Christopher Chapman. In light of this loss, Erez Aminov has been appointed as the new CEO and Chairman. The company also experienced changes in its Board of Directors, with several resignations and new appointments. The leadership transition comes as Telomir continues its focus on developing Telomir-1 for age-related conditions.
Read more →TELOTelomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
Telomir Pharmaceuticals has been added to the Russell 3000 and Russell Microcap Indexes, effective July 1, 2024. This inclusion highlights the company's growth since its IPO and positions it for further success in developing Telomir-1, a novel treatment aimed at age-related conditions. The Russell indexes are significant benchmarks for investment strategies.
Read more →TELOTelomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Telomir Pharmaceuticals announced that its scientific advisor, Dr. Adam Kaplin, will participate in a panel at the DIA Global Annual Meeting on June 17, 2024. The panel will focus on the use of generative AI in clinical trials, aiming to improve efficiency and safety in drug development. This opportunity showcases Telomir's commitment to leveraging innovative technologies in its research.
Read more →TELOTelomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Telomir Pharmaceuticals has initiated pivotal studies for its lead product candidate, Telomir-1, focusing on its safety and efficacy in geriatric canines. The study commenced on May 28, 2024, with initial doses well-tolerated by the animals. This research aims to provide insights into treating age-related conditions, potentially benefiting both pets and humans.
Read more →TELOTelomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
Telomir Pharmaceuticals, Inc. has signed a media deal with New to The Street to feature its management in interviews and advertisements aimed at promoting its TELOMIR-1 drug, which targets age-related diseases. This agreement includes broadcasts on Bloomberg TV and the FOX Business Network, alongside digital advertising across New York City. The company is in the pre-clinical stage of developing TELOMIR-1, which aims to reverse age-related inflammation conditions. Management expresses optimism regarding the drug's potential and the increased exposure from the media partnership.
Read more →TELOTelomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals presented promising pre-clinical data on its age-reversal drug, Telomir-1, at a National Press Club event. The drug showed a 40% increase in telomerase activity and lengthened telomeres in vitro. The company plans to initiate human and animal trials for osteoarthritis in 2025, highlighting its commitment to addressing age-related conditions.
Read more →TELOTelomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir Pharmaceuticals announced that Dr. Michael F. Roizen will present pre-clinical data for Telomir-1, a drug aimed at reversing age-related conditions, at the National Press Club on April 15, 2024. The data suggests that Telomir-1 may elongate telomeres, potentially stimulating stem cell renewal. The event aims to share findings with the public and the longevity community.
Read more →TELOUPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Telomir Pharmaceuticals has partnered with Argenta to conduct a study on Telomir-1's efficacy in treating osteoarthritis in canines. This three to six-month study aims to evaluate the treatment's impact on the disease's progression. The results could also support future human trials for osteoarthritis. The initiative addresses a significant unmet need in canine healthcare.
Read more →TELOTelomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Telomir Pharmaceuticals has announced a collaboration with Argenta to conduct a study on Telomir-1, focusing on its efficacy in treating osteoarthritis and other age-related conditions in canines. This research marks a significant step as it is the first known study aimed at reversing aging in dogs. The study will assess Telomir-1's effects through various evaluations, with hopes that positive results may pave the way for future human trials. Currently, millions of canines suffer from osteoarthritis, and existing treatments only alleviate symptoms rather than address the disease itself.
Read more →TELOTelomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
Telomir Pharmaceuticals announced the upcoming presentation of pre-clinical data for its lead product, Telomir-1, at the Global Longevity Federation Conference. The data suggests that Telomir-1 can elongate telomeres in human cells, potentially addressing age-related conditions. This follows previous presentations and highlights the company's commitment to longevity research.
Read more →TELOTelomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
Telomir Pharmaceuticals is utilizing AI-driven models to explore the potential of its lead product candidate, Telomir-1, in reversing age-related conditions. The company has presented promising findings from its pre-clinical studies, suggesting that Telomir-1 may help lengthen DNA's protective telomeres. Telomir plans to further showcase its research at an upcoming conference in Las Vegas.
Read more →TELOTelomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Telomir Pharmaceuticals presented promising pre-clinical data for its lead product, Telomir-1, at the NUHS Centre for Healthy Longevity Conference 2024 in Singapore. The data indicates that Telomir-1 can extend telomere length across several human cell lines, suggesting its potential efficacy in addressing age-related conditions. The findings bolster the company's claim that Telomir-1 may play a significant role in aging reversal. Additionally, Telomir's partnership with InSilicoTrials aims to enhance the drug's development efficiency through AI modeling.
Read more →TELOTelomir Pharmaceuticals Announces Closing of Initial Public Offering
Telomir Pharmaceuticals, Inc. has successfully closed its initial public offering, raising $7 million through the sale of 1,000,000 shares at $7.00 each. The shares commenced trading on February 9, 2024, under the Nasdaq ticker TELO. The company focuses on developing Telomir-1, a novel small molecule aimed at lengthening DNA's telomere caps for age reversal. While the IPO marks a significant milestone, Telomir operates in the pre-clinical stage, indicating further challenges ahead in drug development and market acceptance.
Read more →TELOTelomir Pharmaceuticals Announces Pricing of Initial Public Offering Baltimore, Maryland
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, has announced the pricing of its initial public offering (IPO) at $7.00 per share, aiming to raise $7 million. The IPO is set to close on February 13, 2024, with shares expected to start trading on the Nasdaq under the ticker 'TELO' on February 9, 2024. The company is focused on developing TELOMIR-1, a novel small molecule intended for age reversal through the lengthening of DNA's protective telomere caps. Additionally, the therapeutic aims to address age-related inflammatory conditions, with hemochromatosis as its initial target.
Read more →Competitive Position
How TELO ranks across every disease it competes inCompetitive Position is a premium feature
See how TELO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial